ImmunityBio, Inc. (IBRX)

ImmunityBio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	75.67	88.33	143.43	265.45	104.64	181.1
Short-Term Investments	281.7	154.48	6.38	1.01	2.54	136.02
Cash & Short-Term Investments	357.37	242.82	149.81	266.46	107.18	317.12
Cash Growth	132.58%	62.09%	-43.78%	148.60%	-66.20%	230.12%
Accounts Receivable	53.47	42.57	2.36	-	-	-
Other Receivables	0.03	0.05	0.29	2.02	1.89	1.33
Total Trade Receivables	53.5	42.62	2.65	2.02	1.89	1.33
Inventory	1.94	0.91	8.27	-	-	-
Other Current Assets	26.17	28.53	23.85	25.6	31.5	15.9
Total Current Assets	438.98	314.88	184.59	294.08	140.58	334.35
Net Property, Plant & Equipment	145.49	147.27	170.46	182.63	189.45	119.17
Other Intangible Assets	-	-	-	-	20	1.42
Goodwill	11.84	13.95	15.93	17.09	-	-
Long-Term Investments	-	7.38	7.13	7.77	7.47	7.2
Other Long-Term Assets	32.19	18.42	4.83	2.88	4.86	6.78
Total Assets	628.5	501.9	382.93	504.45	362.36	468.91

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	12	6.98	6.73	9.2	21.02	11.42
Accrued Expenses	55.67	46.84	40.58	42.71	41.83	51.39
Short-Term Debt	-	-	-	-	431.9	299.24
Current Portion of Leases	7.51	7.54	7.47	5.24	2.65	3.01
Other Current Liabilities	1.55	0.4	0.17	1.14	3.47	3.94
Total Current Liabilities	76.73	61.75	54.94	58.28	500.86	369
Long-Term Debt	1,189	801.71	746.28	836.95	241.27	306.35
Long-Term Leases	31.2	33.45	34.82	39.94	47.95	37.07
Other Long-Term Liabilities	376.9	104.56	35.01	155.21	22.09	0.41
Total Long-Term Liabilities	1,598	939.72	816.12	1,032	311.32	343.83
Total Liabilities	1,674	1,001	871.06	1,090	812.18	712.82

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.11	0.1	0.09	0.07	0.04	0.04
Additional Paid-in Capital	3,516	3,197	2,885	2,375	1,931	1,720
Accumulated Other Comprehensive Income	27.28	28.96	1.2	0.01	0.18	0
Retained Earnings	-4,590	-3,727	-3,375	-2,962	-2,378	-1,962
Total Common Shareholders' Equity	-1,047	-500.47	-489.1	-586.99	-447.33	-242.17
Minority Interest	0.87	0.9	0.97	1.05	-2.49	-1.74
Shareholders' Equity	-1,046	-499.57	-488.13	-585.94	-449.82	-243.91
Total Liabilities & Equity	628.5	501.9	382.93	504.45	362.36	468.91

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,228	842.69	788.57	882.14	723.77	645.66
Net Cash (Debt)	-870.78	-599.87	-638.76	-615.68	-616.59	-328.55
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.87	-0.65	-0.91	-1.21	-1.54	-0.84
Book Value	-1,047	-500.47	-489.1	-586.99	-447.33	-242.17
Book Value Per Share	-1.04	-0.54	-0.70	-1.15	-1.12	-0.62
Tangible Book Value	-1,058	-514.42	-505.03	-604.08	-467.33	-243.59
Tangible Book Value Per Share	-1.05	-0.56	-0.72	-1.19	-1.17	-0.63

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Aug 4, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 6, 2026

Data Sources Report a data error